About 4,120 results

ALLMedicine™ Patent Foramen Ovale Center

Research & Reviews  1,350 results

Application of Transesophageal Echocardiography in Amplatzer Atrial Septal Defect Occlu...
Cardiovascular Therapeutics; Du Y, Xie H et. al.

Aug 9th, 2022 - The Amplatzer patent foramen ovale (PFO) occluder is the most commonly used device for percutaneous closure of a large PFO. However, its use may predispose the patient to postoperative residual shunting. To reduce the incidence of residual shuntin...

Hemodynamic and Anatomic Changes after Fetal Aortic Valvuloplasty are associated with P...
Prenatal Diagnosis; Bradford VR, Tworetzky W et. al.

Aug 5th, 2022 - There are minimal data characterizing the trajectory of left heart growth and hemodynamics following fetal aortic valvuloplasty (FAV). This retrospective study included patients who underwent FAV between 2000 and 2019 with echocardiograms performe...

The skinny on post-patent foramen ovale closure atrial fibrillation.
Catheterization and Cardiovascular Interventions : Offici... Mojadidi MK, Tobis JM

Aug 4th, 2022 - The skinny on post-patent foramen ovale closure atrial fibrillation.|2022|Mojadidi MK,Tobis JM,|diagnosis,etiology,therapy,adverse effects,complications,diagnostic imaging,therapy,

Bilateral Transbrachial Intracardiac Echocardiography-Guided Patent Foramen Ovale Closu...
The Journal of Invasive Cardiology; Chiang M, Wang DD et. al.

Aug 4th, 2022 - Patent foramen ovale (PFO) closure is a very common procedure, and unfavorable femoral venous access is not uncommonly encountered. The ability to treat this common condition in a minimally invasive manner via a different access is important in ou...

Double Interatrial Septum and Patent Foramen Ovale in Woman With Transient Ischemic Att...
Texas Heart Institute Journal; Jurinjak SJ, Vincelj J et. al.

Jul 27th, 2022 - Double Interatrial Septum and Patent Foramen Ovale in Woman With Transient Ischemic Attack.|2022|Jurinjak SJ,Vincelj J,Starcevic B,Delic-Brkljacic D,|

see more →

Guidelines  5 results

SCAI expert consensus statement on operator and institutional requirements for PFO clos...
Catheterization and Cardiovascular Interventions : Offici... Horlick E, Kavinsky CJ et. al.

Mar 22nd, 2019 - Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary prevention of recurrent stroke has been controversial. Publication of high-quality evidence from randomized clinical trials and the subsequent FDA approval of two...

Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for...
BMJ (Clinical Research Ed.); Kuijpers T, Spencer FA et. al.

Jul 27th, 2018 - Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline.|2018|Kuijpers T,Spencer FA,Siemieniuk RAC,Vandvik PO,Otto CM,|therapeutic use,methods,surgery,...

Guidelines for the primary prevention of stroke: a statement for healthcare professiona...
Stroke Meschia JF, Bushnell C et. al.

Oct 31st, 2014 - The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of stroke among individuals who have not previously experienced a stroke or transient ischemic attack. Evidence-based recomme...

Management of patients with patent foramen ovale and cryptogenic stroke: a collaborativ...
Catheterization and Cardiovascular Interventions : Offici... Pristipino C, Anzola GP et. al.

Jun 22nd, 2013 - To organize a common approach on the management of patent foramen ovale (PFO) and cryptogenic stroke that may be shared by different specialists. The management of PFO related to cryptogenic stroke is controversial, despite an increase in interven...

Valvular and structural heart disease: American College of Chest Physicians Evidence-Ba...
Chest Salem DN, O'Gara PT et. al.

Jul 24th, 2008 - This chapter about antithrombotic therapy for valvular heart disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits d...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  98 results

Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia

Jul 25th, 2022 - AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design). The interventional phase is followed by an observational phase as long as the patient is implanted...

Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion.

Jul 22nd, 2022 - The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurre...

Post Market Registry of the CBSO

Jul 21st, 2022 - Multi centre, international, post market registry to monitor the clinical performance and safety of an atrial septal closure device with biodegradable framework in patients with clinically significant atrial septum defect (ASD) or patent foramen o...

Evaluation of the Efficacy and Safety of a Simplified Procedure for the Percutaneous Closure of the Patent Foramen Ovale

Jun 30th, 2022 - Patent Foramen Ovale, is an embryonic remnant, formed by apposition of the septum primum and septum secondum composing the interatrial septum. This foramen ovale is permeable during intra-uterine life and allows inter-auricular communication. It t...

GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Jun 7th, 2022 - A maximum of 636 adult subjects will be enrolled at up to 40 U.S. centers. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 5 years post implant.

see more →

News  190 results

Patent Foramen Ovale Clinical Practice Guidelines (SCAI, 2022)

May 27th, 2022 - Clinical practice guidelines on the management of patent foramen ovale (PFO) from the Society for Cardiovascular Angiography and Interventions (SCAI) were published in May 2022 in  JSCAI.[1] In patients aged 18-60 years who have had a PFO-related ...

SCAI issues guidelines for PFO management, makes case for expansion
Richard Mark Kirkner

May 20th, 2022 - The first-ever guidelines for interventional cardiologists using percutaneous patent foramen ovale closure recommend expanding the use of the procedure beyond the Food and Drug Administration–approved indication following PFO-associated ischemic s.

SCAI Issues Guidelines for PFO Management, Makes Case for Expansion

May 20th, 2022 - The first-ever guidelines for interventional cardiologists using percutaneous patent foramen ovale closure recommend expanding the use of the procedure beyond the Food and Drug Administration-approved indication following PFO-associated ischemic s...

Embolic Stroke of Undetermined Source in the Young: Low Recurrence, but Few Answers

Mar 14th, 2022 - Embolic stroke of undetermined source (ESUS) in younger patients doesn't often lead to recurrence -- or provide much of a clue to its causes, a large longitudinal study showed. Ischemic stroke or death occurred in 3.0% of patients ages 50 and youn...

Robotic Transcranial Doppler Improves PFO Detection After Stroke

Feb 17th, 2022 - The use of a robotic-assisted device to perform transcranial Doppler ultrasound greatly improved the detection of right-to-left cardiac shunts in patients with presumed embolic strokes compared with the current standard of care — transthoracic ech...

see more →

Patient Education  4 results see all →